ISOLA THERAPEUTICS INC

Isola Therapeutics Inc. specializes in translational research and development of novel drug delivery systems for targeted therapeutic interventions in pulmonary and esophageal pathologies. The company leverages endobronchial and endoesophageal lavage technologies to repurpose existing pharmaceutical agents for acute chemical threat mitigation and cancer treatment, demonstrating deep expertise in localized drug administration, aerosol pharmacokinetics, and preclinical model validation. Their work bridges life sciences innovation with defense and public health preparedness, focusing on non-invasive, high-precision delivery platforms that enhance bioavailability while minimizing systemic toxicity. Key differentiators include proprietary lavage-based delivery methodologies, adaptive formulation science, and a strong focus on repurposing therapeutics under urgent biomedical threat scenarios. The contractor maintains a focused relationship with the Department of Health and Human Services, delivering R&D solutions aligned with biomedical preparedness and oncology innovation. Their engagements center on advancing medical countermeasures against chemical agents and developing novel treatment paradigms for gastrointestinal and respiratory cancers, reflecting a strategic alignment with HHS priorities in public health resilience and precision medicine. Isola Therapeutics operates primarily within the biotechnology and life sciences R&D sectors, with NAICS 541714 and 541715 defining their core market space. They position themselves as a niche innovator in non-systemic drug delivery, serving government-funded programs focused on emergency response, oncology therapeutics, and targeted pharmacology. Their work sits at the intersection of biomedical engineering, pharmacology, and clinical translation, with minimal overlap into broader biotech domains like genomics or nanotechnology. As a small business structured as a 2L entity based in Minneapolis, Minnesota, Isola Therapeutics operates without federal certifications but maintains a focused government market presence through specialized R&D contracts. Their geographic footprint supports collaboration with regional academic and medical research institutions, reinforcing their role as a nimble, science-driven contractor in the federal biomedical innovation ecosystem.